Replies to post #41787 on China Growth Stocks

[Drexion2004]

CKGT: Don't you normally take out 'one time charges' and 'one time gains' when calculating run-rate though? Its kind of unfair to compare the two years if one gets some abnormal non-repeatable bonanza of profit. Not really an apples to apples comparison.

-Fernando

[BiotechValues]

CKGT: Well, I'm expecting big time revenue and net income growth from CKGT this year.

This is why:

Take away the GAAP vs. non-GAAP issues (and no matter which you prefer too look at it, CKGT had 66% growth in sales, adjusted net income (taking out the warrant revaluation) rose 21%, and income from operations rose 1.2 million from $880,530 in their historically weakest quarter of the year.

Now, add to that, the fact that in April 2010 they announced a nationwide retailing agreement to sell their products in 3,000 new points of sale throughout China, and I feel quite confident that CKGT will have a very strong year. Keep in mind that their highest margins are in the products they'll now sell through 3000 stores that they didn't even have access to in Q1.

April 5, 2010: China Kangtai Cactus Biotech Signs Sales Agreement with Chinese Retailer To Market Cactus-Based Health Products Across China

http://ih.advfn.com/p.php?pid=nmona&article=42251507&symbol=CKGT

As they say on Yahoo!, "MARK THIS POST". I'll come back to it at the eoy when CKGT is $3+